Advertisement
UK markets closed

  • FTSE 100

    8,146.86
    -16.81 (-0.21%)
     

  • FTSE 250

    20,120.36
    -75.59 (-0.37%)
     

  • AIM

    776.04
    -4.39 (-0.56%)
     

  • GBP/EUR

    1.1845
    -0.0034 (-0.29%)
     

  • GBP/USD

    1.2686
    -0.0074 (-0.58%)
     

  • Bitcoin GBP

    52,189.56
    -61.25 (-0.12%)
     

  • CMC Crypto 200

    1,369.59
    -48.29 (-3.41%)
     

  • S&P 500

    5,431.60
    -2.14 (-0.04%)
     

  • DOW

    38,589.16
    -57.94 (-0.15%)
     

  • CRUDE OIL

    78.49
    -0.13 (-0.17%)
     

  • GOLD FUTURES

    2,348.40
    +30.40 (+1.31%)
     

  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     

  • HANG SENG

    17,941.78
    -170.85 (-0.94%)
     

  • DAX

    18,002.02
    -263.66 (-1.44%)
     

  • CAC 40

    7,503.27
    -204.75 (-2.66%)
     
Brands:

How I founded Britain's most respected removals firm

'Doing removals defines you for the rest of your working life'

Sector Update: Health Care Stocks Slightly Higher Late Afternoon

MT Newswires
·1-min read

Health care stocks were slightly higher late Wednesday afternoon, with the NYSE Health Care Index edging up 0.1% and the Health Care Select Sector SPDR Fund (XLV) adding 0.2%.

The iShares Biotechnology ETF (IBB) gained 0.7%.

In corporate news, Pfizer (PFE) said Wednesday that the first phase of its multiyear cost-cutting program focuses on operational efficiencies and will generate savings of about $1.5 billion by 2027. Its shares spiked 3.7%.

Anavex Life Sciences (AVXL) shares were up more than 3% after the firm reported new appointments to its leadership team.

Biogen (BIIB) struck a deal to buy privately held Human Immunology Biosciences for up to $1.8 billion, expanding its rare disease pipeline with an investigational candidate that aims to treat a kidney-specific disease. Biogen shares were 1.1% lower.

Amphastar Pharmaceuticals (AMPH) shares gained 3.7% after the US Food and Drug Administration approved its abbreviated new drug application for albuterol sulfate inhalation aerosol to treat bronchospasm in patients aged four and older.